SIRT-Y90 with Atezolizumab and Bevacizumab for unresectable liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational bidirectional cohort study conducted across approximately eight sites in China. It combines retrospective data on prior treatments and outcomes with prospective follow-up to assess long-term recurrence, progression, and survival after starting SIRT-Y90 in combination with atezolizumab and bevacizumab. Primary endpoint is objective response rate using RECIST 1.1 and mRECIST, with secondary endpoints including progression-free survival, overall survival, and AFP reduction. Eligible patients are adults with unresectable HCC who have received at least one cycle of the triple therapy (or SIRT-Y90 alone in some cases) and have at least one post-treatment visit recorded. The analysis will describe efficacy and safety in this real-world setting in China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years old A diagnosis of unresectable HCC was made. HCC can be diagnosed clinically or pathologically.

At least one Atezo plus Bev administration and one cycle of SIRT-Y90 treatment. At least one visit was recorded after the initiation of Atezo + Bev and SIRT-Y90

Exclusion Criteria:

* Concomitant cancers other than BCC were diagnosed before or at the start of Atezo + Bev or SIRT-Y90 Participate in an interventional clinical study before or at the time of initiation of treatment with Atezo + Bev or SIRT-Y90

Where it's running

• No. 777, Xitai Road, Chang'an District, Xi'an City, Shaanxi Province, China
  Xi’an, Shanxi, China Recruiting

Study contacts

• Study coordinator: GuoHong Han, Doctor of Medicine
• Email: yingxiangZYL@163.com
• Phone: 18234507085

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TACE plus SBRT before liver transplant for hepatocellular carcinoma

  This study tests whether adding SBRT to standard TACE helps liver transplant patients with hepatocellular carcinoma see better outcomes.

  Recruiting AIO-Studien-gGmbH · München · NCT07924943

• Personalized 3D-printed liver models to pick adjuvant therapy after liver cancer surgery

  Doctors test whether a patient’s own 3D-bioprinted liver model can help choose the best additional treatment to lower the chance of cancer coming back after liver surgery.

  Recruiting The University of Hong Kong · Hong Kong · NCT07839767

• Real-world view of systemic therapies for advanced HCC at a single center

  This study looks at how patients with advanced hepatocellular carcinoma respond to systemic treatments in real-world practice at Mansoura University Hospitals.

  Recruiting Mansoura University · Al Mansurah, Dakahlia Governorate · NCT07814014

• Laparoscopic liver and spleen removal for small liver cancer in people with cirrhosis and enlarged spleen

  This study tests whether removing part of the liver and the spleen during one operation helps people with small liver cancers and hypersplenism by improving liver function and immune balance.

  Recruiting Northern Jiangsu People's Hospital · Yangzhou, Jiangsu · NCT07811687

• ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients

  This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.

  Recruiting at 2 sites Tam Anh Research Institute · Hanoi, Hanoi and 1 other locations · NCT07808164

• Iparomlimab and Tuvonralimab with SBRT and Lenvatinib for Potentially Resectable Intermediate-Stage HCC

  This trial tests whether adding two antibodies together with SBRT and lenvatinib can improve outcomes for adults with potentially resectable intermediate-stage hepatocellular carcinoma.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07801287

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.